GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers
NCT ID: NCT06076070
Last Updated: 2023-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10 participants
OBSERVATIONAL
2022-05-25
2024-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan
NCT03542097
Mutational Oncology in Clinical Practice
NCT06020625
CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.
NCT02789384
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
NCT06863870
Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
NCT04621201
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with any histotype of soft tissue sarcomas and bone
* Patients at any stage of the treatment pathway for disease that is localized or metastatic/inoperable
* Availability of follow-up data
* Written informed consent (prospective part/patients in follow-up)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Candiolo Cancer Institute - IRCCS
OTHER
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
NETWORK
Istituto Oncologico Veneto IRCCS
OTHER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Istituto Ortopedico Rizzoli
OTHER
Ospedale Pediatrico Bambin Gesù
OTHER
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Istituti Tumori Giovanni Paolo II
NETWORK
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
OTHER
Regina Elena Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
"Regina Elena" National Cancer Institute
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RS1607/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.